logo

Bio-Path Holdings Inc (BPTH)



Trade BPTH now with
  Date
  Headline
8/26/2019 7:09:39 AM Bio-Path Says Patient Dosing In Amended Phase 2 Prexigebersen Trial In Acute Myeloid Leukemia
8/15/2019 7:14:07 AM Bio-Path Q2 Net Loss $2.5 Mln Or $0.87/shr Vs. Net Loss Of $1.7 Mln Or $2.96/shr Prior Year
1/18/2019 1:00:43 PM Bio-Path Holdings Announces $1.7 Mln Registered Direct Offering
1/17/2019 4:07:35 PM Bio-Path Holdings Announces Closing Of Public Offering Of Common Stock
1/14/2019 10:24:47 PM Bio-Path Prices Underwritten Public Offering Of 8.59 Mln Shares $0.13/shr
1/14/2019 4:02:42 PM Bio-Path Holdings Announces Proposed Public Offering Of Common Stock
12/27/2018 8:51:06 AM Bio-Path Holdings Provides Clinical Update And 2019 Business Outlook
12/3/2018 7:47:18 AM Bio-Path Presents Interim Data From Phase 2 Study Evaluating Prexigebersen As A Treatment For Acute Myeloid Leukemia
9/25/2018 4:15:20 PM Bio-Path Holdings Closes $1.5 Mln Registered Direct Offering
9/21/2018 6:31:50 AM Bio-Path Holdings Plans $1.5 Mln Registered Direct Offering
8/15/2018 7:06:56 AM Bio-Path Q2 Net Loss Attributable To Common Stockholders $1.7 Mln Or $0.15/Shr Vs Loss $3.0 Mln Or $0.31/Shr Last Year
5/16/2018 7:07:28 AM Bio-Path Holdings Q1 Net Loss Widens To $1.9 Mln Or $0.17/shr From $0.4 Mln Or $0.04/shr Last Year
  
 
>